Fig. 1.
Concentration–effect relationship for the inhibition (%) of severe acute respiratory syndrome coronavirus-2 cytopathic activity for remdesivir and ivermectin. For each compound, activity was expressed relative to uninfected/untreated controls (100% inhibition of viral cytopathic activity) and infected/untreated controls (0% inhibition of viral activity). For each compound, activity was assessed at 25.00 µM, 8.33 µM, 2.78 µM, 0.93 µM, 0.31 µM, 0.10 µM and 0.03 µM in triplicate. Data points impacted by drug toxicity were removed automatically. Non-linear regression using an Emax model was performed on data taken from three independent biological replicates in order to generate concentration–effect predictions (solid black lines). For each compound, half maximal effective concentration (EC50) values, hillslope and replicate number (n) are shown. Dashed lines represent EC50 of each compound. Squares, diamonds and circles represent individual biological replicates, and error bars represent standard deviation calculated from technical triplicates.